UBS Group
LYEL icon

UBS Group’s Lyell Immunopharma LYEL Stock Holding History

UBS Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$824K Buy
84,141
+58,159
+224% +$774K ﹤0.01% 5816
2026
Q2 		$365K Sell
25,982
-5,832
-18% -$106K ﹤0.01% 6434
2026
Q1 		$638K Buy
31,814
+18,611
+141% +$435K ﹤0.01% 5897
2025
Q4 		$406K Sell
13,203
-8,039
-38% -$180K ﹤0.01% 6203
2025
Q3 		$345K Sell
21,242
-4,392
-17% -$50.2K ﹤0.01% 6347
2025
Q2 		$227K Buy
25,634
+20,114
+364% +$183K ﹤0.01% 6638
2025
Q1 		$59.4K Sell
5,520
-37,694
-87% -$462K ﹤0.01% 7448
2024
Q4 		$553K Buy
43,214
+37,778
+695% +$749K ﹤0.01% 5770
2024
Q3 		$150K Buy
5,436
+1,195
+28% +$35.1K ﹤0.01% 6071
2024
Q2 		$123K Sell
4,241
-5,718
-57% -$272K ﹤0.01% 6033
2024
Q1 		$444K Sell
9,959
-983
-9% -$42.1K ﹤0.01% 5291
2023
Q4 		$425K Buy
10,942
+1,188
+12% +$42.8K ﹤0.01% 5227
2023
Q3 		$287K Buy
9,754
+2,095
+27% +$99.5K ﹤0.01% 5089
2023
Q2 		$487K Sell
7,659
-3,405
-31% -$188K ﹤0.01% 4847
2023
Q1 		$522K Sell
11,064
-9,487
-46% -$507K ﹤0.01% 4652
2022
Q4 		$1.43M Buy
20,551
+19,535
+1,923% +$1.94M ﹤0.01% 3729
2022
Q3 		$149K Buy
1,016
+755
+289% +$102K ﹤0.01% 5361
2022
Q2 		$34K Buy
261
+11
+4% +$1.12K ﹤0.01% 6264
2022
Q1 		$25K Sell
250
-470
-65% -$56.9K ﹤0.01% 7194
2021
Q4 		$112K Buy
720
+707
+5,438% +$158K ﹤0.01% 6213
2021
Q3 		$4K Buy
+13
New +$3.9K ﹤0.01% 8652

Other funds holding LYEL

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Clearstead Advisors
Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return

UBS Group's LYEL Position: Q3 2026 in Review

UBS Group increased its Lyell Immunopharma (LYEL) stake by 224% in Q3 2026, buying an estimated $774K and bringing the position to 84,141 shares worth $824K. The position accounts for ﹤0.01% of the portfolio, ranked #5816.

UBS Group first reported a position in LYEL in Q3 2021 and has held it in 21 quarters since. The position peaked at $1.43M in Q4 2022. 43 funds tracked by Wall St. Rank hold LYEL as of Q3 2026.

  • UBS Group held 84,141 shares of Lyell Immunopharma worth $824K as of Q3 2026.
  • UBS Group bought 58,159 Lyell Immunopharma shares in Q3 2026, an estimated $774K.
  • Lyell Immunopharma made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #5816 holding.
  • UBS Group first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 21 quarters since.
  • UBS Group's Lyell Immunopharma position peaked at $1.43M in Q4 2022.
  • 43 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.